ZYME

ZymeworksD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$34.99

+43.7% vs current

Most likely

Base case

60%

Probability

Target price

$27.49

+12.9% vs current

B-

Bear case

20%

Probability

Target price

$17.49

-28.2% vs current

AI sentiment snapshot

Latest data as of 2025-11-26

AI commentary

Market tone is cautiously constructive around Zymeworks following recent program updates, but sentiment remains binary given clinical readouts and financing uncertainty [#RankAlpha]. Investor attention centers on partnership prospects and cash guidance as primary re-rating levers [#IR-2024].

RankAlpha Sentiment AI - 2025-11-26

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

-eventClinical-stage program readout (AZD-style bispecific)High impact

Potential binary readout from a mid-stage clinical cohort that would materially re-rate the pipeline if positive; outcome historically binary for similar assets [#PR-2024-11-05].

-catalystQuarterly earnings / cash updateHigh impact

Quarterly cash-burn and guidance updates can trigger dilution concerns or reassure on runway; markets react to late-stage cash commentary [#10Qp5].

-catalystBusiness-development / partnership announcementHigh impact

Deal or licensing announcement could de-risk cash runway and validate platform; Zymeworks has targeted BD previously [#IR-2024].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-26 • Updated nightlySource: Internal modelMethodology